EventsMOL2NET'22, Conference on Molecular, Biomed., Comput. & Network Science and Engineering, 8th ed.
Published
This submission belongs to the session 08. REVIEWWWERS.PUB-08, Reviewers & Pre-Post Publication Workshop, Bilbao-Miami, USA, 2022. of the event MOL2NET'22, Conference on Molecular, Biomed., Comput. & Network Science and Engineering, 8th ed.
Published date
16 Dec, 2022
Academic Editor
author-avatarHumbert G. Díaz
Citation
Test Test, Test, in Proceedings of MOL2NET'22, Conference on Molecular, Biomed., Comput. & Network Science and Engineering, 8th ed., 1 January–15 January 2023, MDPI: Basel, Switzerland, doi: 10.3390/mol2net-08-13874
Share
Email
Facebook
Twitter
LinkedIn

Test

image
1. Test Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia.
Abstract

*Note: Mol2Net conference is associated to different MDPI journals special issues guest edited by Mol2Net Conference Committee members. This is an strategy to increase the online post-publication visibility of papers and conference, promote post-publication brainstorming discussion, and increase authors feedback. This association implies that our conference perform post-publication indexing of selected papers already published in MDPI journals with the consent of the issue editors. We publish free-of-cost these post-publication summaries. They include a shortened title, corresponding author info, and paper cover pdf file. The cover pdf file contains paper first page with all authors, abstract, full reference , and link to original papers.

Reference: This is a post-publication summary note for the paper published in the special issue Sustainable Materials and Technologies for Drug Delivery and Tissue Engineering, Edited by: Dr. I.A. Neacsu and Dr. B.S. Vasile, Managing Editor: C. Zha, Visit the link to see original paper. Pharmaceutics 2022, 14(3), 510; https://doi.org/10.3390/pharmaceutics14030510

Lung cancer is the second-most common cancer and has the highest mortality among all cancer types. Nanoparticle (NP) drug delivery systems have been used to improve the therapeutic effectiveness of lung cancer, but rapid clearance and poor targeting limit their clinical utility. Here, we developed a nanomicelle-microsphere composite, in which doxorubicin (DOX) was loaded with spermine (Spm) modified poly (ethylene glycol)-poly(ε-caprolactone) (PEG-PCL) micelles, and then the nanomicelles were noncovalently adsorbed on the surface of poly (lactic-co-glycolic acid) (PLGA) microspheres. The attachment was confirmed by scanning electron microscopy and confocal microscopy. In vitro cell experiments, MTT assays and intracellular uptake assays were used to demonstrate the cytotoxicity and the cellular uptake of micelles in A549 cells. In vivo biodistribution studies were conducted, an orthotopic lung cancer implantation model based on C57BL/6 mice was established, and then real-time fluorescence imaging analysis was used to study the targeted efficacy of the complex. A nanomicelle-microsphere composite was successively constructed. Moreover, Spm-modified micelles significantly enhanced cytotoxicity and displayed more efficient cellular uptake. Notably, an orthotopic lung cancer implantation model based on C57BL/6 mice was also successively established, and in vivo biodistribution studies confirmed that the complex greatly improved the distribution of DOX in the lungs and displayed notable tumor targeting. These results suggested that the nanomicelle-microsphere composite has potential application prospects in the targeted treatment of lung cancer.

Keywords
Test
Manuscript

Test

Software Resources for Developing Multicriteria Applications: A Review, Part 1: Introduction and types of software resources developed.